Biophytis Reports 2024 Financial Results and 2025 Outlook
- Plans to initiate Phase 2 study in obesity and Phase 3 study in sarcopenia as soon as possible.
- Continued partnership strategy to support the funding of clinical programs.
- Strengthening of the drug discovery platform through the integration of disruptive technologies.
Biophytis announced its financial results for the year ended December 31, 2024, approved by its Board of Directors on July 9, 2025, and presented its strategic outlook. The Company also announces the resumption of trading of its shares on Euronext Growth Paris, effective at market open on July 11, 2025.
Stanislas Veillet, CEO of Biophytis, stated: “2024 was a pivotal year for Biophytis. We confirmed our leadership in sarcopenia drug development and achieved a major milestone in our partnering strategy with the signing of a license agreement with Blanver for Latin America. In 2025, we aim to launch our Phase 2 study in obesity and are actively working to secure a strategic partnership in Asia to fund Phase 3 development in sarcopenia. In parallel, we will strengthen our longevity drug discovery platform by integrating disruptive technologies.”